Thyronamines - Past, present, and future

S. Piehl, C. S. Hoefig, Thomas (Tom) Scanlan, Josef Köhrle

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Thyronamines (TAMs) are a newly identified class of endogenous signaling compounds. Their structure is identical to that of thyroid hormone and deiodinated thyroid hormone derivatives, except that TAMs do not possess a carboxylate group. Despite some initial publications dating back to the 1950s, TAMs did not develop into an independent area of research until 2004, when they were rediscovered as potential ligands to a class of G protein-coupled receptors called trace-amine associated receptors. Since this discovery, two representatives of TAMs, namely 3-iodothyronamine (3-T 1AM) and thyronamine (T 0AM), have been detected in vivo. Intraperitoneal or central injection of 3-T 1AM or T 0AM into mice, rats, or Djungarian hamsters caused various prompt effects, such as metabolic depression, hypothermia, negative chronotropy, negative inotropy, hyperglycemia, reduction of the respiratory quotient, ketonuria, and reduction of fat mass. Although their physiological function remains elusive, 3-T 1AM and T 0AM have already revealed promising therapeutic potential because they represent the only endogenous compounds inducing hypothermia as a prophylactic or acute treatment of stroke and might thus be expected to cause fewer side effects than synthetic compounds. This review article summarizes the still somewhat scattered data on TAMs obtained both recently and more than 20 yr ago to yield a complete and updated picture of the current state of TAM research.

Original languageEnglish (US)
Pages (from-to)64-80
Number of pages17
JournalEndocrine Reviews
Volume32
Issue number1
DOIs
StatePublished - Feb 2011

Fingerprint

Hypothermia
Thyroid Hormones
Phodopus
Ketosis
G-Protein-Coupled Receptors
thyronamine
Research
Hyperglycemia
Amines
Publications
Stroke
Fats
Ligands
Injections
Therapeutics
3-iodothyronamine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Thyronamines - Past, present, and future. / Piehl, S.; Hoefig, C. S.; Scanlan, Thomas (Tom); Köhrle, Josef.

In: Endocrine Reviews, Vol. 32, No. 1, 02.2011, p. 64-80.

Research output: Contribution to journalArticle

Piehl, S, Hoefig, CS, Scanlan, TT & Köhrle, J 2011, 'Thyronamines - Past, present, and future', Endocrine Reviews, vol. 32, no. 1, pp. 64-80. https://doi.org/10.1210/er.2009-0040
Piehl, S. ; Hoefig, C. S. ; Scanlan, Thomas (Tom) ; Köhrle, Josef. / Thyronamines - Past, present, and future. In: Endocrine Reviews. 2011 ; Vol. 32, No. 1. pp. 64-80.
@article{22a1b1f52b0f462488216955d83da01b,
title = "Thyronamines - Past, present, and future",
abstract = "Thyronamines (TAMs) are a newly identified class of endogenous signaling compounds. Their structure is identical to that of thyroid hormone and deiodinated thyroid hormone derivatives, except that TAMs do not possess a carboxylate group. Despite some initial publications dating back to the 1950s, TAMs did not develop into an independent area of research until 2004, when they were rediscovered as potential ligands to a class of G protein-coupled receptors called trace-amine associated receptors. Since this discovery, two representatives of TAMs, namely 3-iodothyronamine (3-T 1AM) and thyronamine (T 0AM), have been detected in vivo. Intraperitoneal or central injection of 3-T 1AM or T 0AM into mice, rats, or Djungarian hamsters caused various prompt effects, such as metabolic depression, hypothermia, negative chronotropy, negative inotropy, hyperglycemia, reduction of the respiratory quotient, ketonuria, and reduction of fat mass. Although their physiological function remains elusive, 3-T 1AM and T 0AM have already revealed promising therapeutic potential because they represent the only endogenous compounds inducing hypothermia as a prophylactic or acute treatment of stroke and might thus be expected to cause fewer side effects than synthetic compounds. This review article summarizes the still somewhat scattered data on TAMs obtained both recently and more than 20 yr ago to yield a complete and updated picture of the current state of TAM research.",
author = "S. Piehl and Hoefig, {C. S.} and Scanlan, {Thomas (Tom)} and Josef K{\"o}hrle",
year = "2011",
month = "2",
doi = "10.1210/er.2009-0040",
language = "English (US)",
volume = "32",
pages = "64--80",
journal = "Endocrine Reviews",
issn = "0163-769X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Thyronamines - Past, present, and future

AU - Piehl, S.

AU - Hoefig, C. S.

AU - Scanlan, Thomas (Tom)

AU - Köhrle, Josef

PY - 2011/2

Y1 - 2011/2

N2 - Thyronamines (TAMs) are a newly identified class of endogenous signaling compounds. Their structure is identical to that of thyroid hormone and deiodinated thyroid hormone derivatives, except that TAMs do not possess a carboxylate group. Despite some initial publications dating back to the 1950s, TAMs did not develop into an independent area of research until 2004, when they were rediscovered as potential ligands to a class of G protein-coupled receptors called trace-amine associated receptors. Since this discovery, two representatives of TAMs, namely 3-iodothyronamine (3-T 1AM) and thyronamine (T 0AM), have been detected in vivo. Intraperitoneal or central injection of 3-T 1AM or T 0AM into mice, rats, or Djungarian hamsters caused various prompt effects, such as metabolic depression, hypothermia, negative chronotropy, negative inotropy, hyperglycemia, reduction of the respiratory quotient, ketonuria, and reduction of fat mass. Although their physiological function remains elusive, 3-T 1AM and T 0AM have already revealed promising therapeutic potential because they represent the only endogenous compounds inducing hypothermia as a prophylactic or acute treatment of stroke and might thus be expected to cause fewer side effects than synthetic compounds. This review article summarizes the still somewhat scattered data on TAMs obtained both recently and more than 20 yr ago to yield a complete and updated picture of the current state of TAM research.

AB - Thyronamines (TAMs) are a newly identified class of endogenous signaling compounds. Their structure is identical to that of thyroid hormone and deiodinated thyroid hormone derivatives, except that TAMs do not possess a carboxylate group. Despite some initial publications dating back to the 1950s, TAMs did not develop into an independent area of research until 2004, when they were rediscovered as potential ligands to a class of G protein-coupled receptors called trace-amine associated receptors. Since this discovery, two representatives of TAMs, namely 3-iodothyronamine (3-T 1AM) and thyronamine (T 0AM), have been detected in vivo. Intraperitoneal or central injection of 3-T 1AM or T 0AM into mice, rats, or Djungarian hamsters caused various prompt effects, such as metabolic depression, hypothermia, negative chronotropy, negative inotropy, hyperglycemia, reduction of the respiratory quotient, ketonuria, and reduction of fat mass. Although their physiological function remains elusive, 3-T 1AM and T 0AM have already revealed promising therapeutic potential because they represent the only endogenous compounds inducing hypothermia as a prophylactic or acute treatment of stroke and might thus be expected to cause fewer side effects than synthetic compounds. This review article summarizes the still somewhat scattered data on TAMs obtained both recently and more than 20 yr ago to yield a complete and updated picture of the current state of TAM research.

UR - http://www.scopus.com/inward/record.url?scp=79951605794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951605794&partnerID=8YFLogxK

U2 - 10.1210/er.2009-0040

DO - 10.1210/er.2009-0040

M3 - Article

VL - 32

SP - 64

EP - 80

JO - Endocrine Reviews

JF - Endocrine Reviews

SN - 0163-769X

IS - 1

ER -